Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 1

Conditions

Allergic Rhinitis

Treatments

Drug: Fluticasone Propionate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00348361

ELR100710

Details and patient eligibility

About

This study is aimed at validating key therapeutic targets and biomarkers associated with allergic rhinitis. The therapeutic target expression will be investigated after a 7 day course of corticosteroid treatment followed by allergen challenge.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

No signs or symptoms of rhinitis outside of the relevant airborne allergen season.

Exclusion criteria

History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessments.
Symptoms of rhinitis at inclusion indicated by total VAS score of >40 for the combined symptoms scores for blockage, rhinorrhoea, sneezing, itching) or a single symptom with a VAS score >20.
Subjects not showing a nasal response to allergen concentration =< 10,000 BU/ml.
Subjects with positive skin prick test for Dust House Mite.